Nancy Stagliano, Neuron23 CEO
March 30, 2022 05:00 AM EDTUpdated 01:56 PM
Financing

Chas­ing Bris­tol My­ers and Bio­gen/De­nali, CNS biotech rais­es $100M in dash to­ward clin­ic

Paul Schloesser

Associate Editor

In the months af­ter South San Fran­cis­co-based Neu­ron23 an­nounced a com­bined Se­ries A and Se­ries B, the biotech sat back down at the ne­go­ti­at­ing ta­ble …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times